Angiotech Pharmaceuticals

Angiotech is a pharmaceutical company in Vancouver, British Columbia, Canada. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Angiotech Pharmaceuticals Inc
TypePublic
IndustryPharmaceutical
Founded1992 
Headquarters
Vancouver, British Columbia
,
Canada
Key people
K. Thomas Bailey
Number of employees
1450[1]
Websitewww.angiotech.com

In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins.

Angiotech, based in Vancouver, British Columbia, was founded in 1992 by William L. Hunter, M.D., Lindsay Machan, M.D., and Larry Arsenault, Ph.D.

In 2017, Angiotech was acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital. [2]

References
  1. "Company Profile for Angiotech Pharmaceuticals Inc (CA;ANP)". Archived from the original on 2012-02-29. Retrieved 2008-10-10.
  2. Falconer, Kirk (2016-12-19). "Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group". PE Hub. Retrieved 2019-10-28.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.